Cullinan Oncology, Inc. (CGEM)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Cullinan Oncology, Inc. (CGEM) is up 48.2% since the beginning of the year. At $15 per share, CGEM is trading 8.4% below its 52-week high of $17. Investors who bought $1,000 worth of CGEM shares 5 years ago would now be looking at an investment worth $516.

Cullinan Oncology, Inc. (CGEM) has returned 48.21% so far this year and 71.21% over the past 12 months.

Based on dividend-adjusted daily data since Jan 8, 2021, CGEM's average daily return is +0.05%, while the average monthly return is +0.40%. At this rate, an investment would double in approximately 14.5 years.

Historically, 41% of months were positive and 59% were negative. The best month was Apr 2024 with a return of +58.5%, while the worst month was Mar 2022 at -27.0%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 7 months.

On a daily basis, CGEM closed higher 48% of trading days. The best single day was Nov 24, 2025 with a return of +36.5%, while the worst single day was Mar 4, 2021 at -17.0%.

Cullinan Oncology, Inc. has an annualized alpha of -6.69%, beta of 1.29, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since January 11, 2021.

• This stock participated in 50.86% of S&P 500 Index downside but only -12.92% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CGEM ranks 73 for risk / return — better than 73% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Cullinan Oncology, Inc. (CGEM) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Cullinan Oncology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cullinan Oncology, Inc. was 89.24%, occurring on Oct 2, 2025. The portfolio has not yet recovered.

The current Cullinan Oncology, Inc. drawdown is 71.28%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Cullinan Oncology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Cullinan Oncology, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.